Migraine. Migraine
Conditions
Interventions
Intervention 1: Zonisamide capsule, 50-200 mg once day for 3 months in the intervention group. Intervention 2: topiramate tablet 25-100 mg/day BID or twice in day for 3 month in control group.
Treatment - Drugs
Zonisamide capsule, 50-200 mg once day for 3 months in the intervention group
topiramate tablet 25-100 mg/day BID or twice in day for 3 month in control group
Sponsors
Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: history of classic or common migraine that met International Headache Society (HIS) criteria, which is at least one year of past disease, number of migraine attacks at least four times per month and less than 15 times per month, or even when they occur less than four times per month but migraine attacks are very prolonged and debilitating that require preventive treatment, postmenopausal women who pass at least one year of their menopause, negative pregnancy test, using appropriate contraceptive during the study, no consumption of topiramate or Zonisamide Exclusion criteria: suffering from other than migraine headaches such as tension headaches, periodic headaches and sinusitis, presence of any cause of pain that must be used medications regularly, history of hypersensitivity to topiramate or zonisamide
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache frequency. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire.;Use of acute medication. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire.;Headache severity. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire.;MIDAS score. Timepoint: before trial and 3 month after trial. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drugs complications. Timepoint: before trial, 1 month and 3 months after trial. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Vahid Abbasi
Ahvaz Jundishapur University of Medical Sciences
Outcome results
None listed